



Pfizer Pipeline

As of February 28, 2011

Disclaimer

- As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from Phase 3 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of February 28, 2011.
- Visit Pfizer.com/pipeline, Pfizer's online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.

Table of Contents

Pfizer Pipeline Snapshot	4
Cardiovascular & Metabolic Diseases	5
Inflammation & Immunology	6
Neuroscience & Pain	7
Oncology	9
Vaccines	10
Other Areas of Focus	11
Projects Discontinued Since Last Update	13

Pfizer Pipeline Snapshot




Pipeline represents progress of R&D programs since 9/27/10
Included are 93 NMEs plus 25 additional indications

15 Projects discontinued since last update

Recent Approval
Xiapex for Dupuytren's Contracture (E.U.)

Pfizer Pipeline Snapshot as of September 27, 2010



Pipeline represents progress of R&D programs since 1/27/10
Included are 92 NMEs plus 26 additional indications

31 Projects discontinued since last update



Pfizer Pipeline – February 28, 2011

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Cardiovascular and Metabolic Diseases	apixaban	Factor Xa Inhibitor	Venous Thromboembolism Prevention (E.U.)	Registration
	Viviant	Selective Estrogen Receptor Modulator	Osteoporosis Treatment and Prevention	Registration
	Pristiq	Serotonin Norepinephrine Reuptake Inhibitor	Vasomotor Symptoms of Menopause	Registration
	apixaban	Factor Xa Inhibitor	Atrial Fibrillation	Phase 3
	apixaban	Factor Xa Inhibitor	Venous Thromboembolism Treatment	Phase 3
	PF-04971729		Diabetes Mellitus-Type 2	Phase 2
	PF-00489791		Raynaud's Syndrome	Phase 2
	Revatio IV		Cardiac Surgery	Phase 2
	► PF-05230901		Cachexia (Biologic)	Phase 1
	CVX 096 (PF-04856883)		Diabetes Mellitus-Type 2 (Biologic)	Phase 1
	OAP-189 (PF-05212389)		Diabetes Mellitus-Type 2, Obesity (Biologic)	Phase 1
	PF-03882845		Diabetic Nephropathy	Phase 1
	PF-04620110		Diabetes Mellitus-Type 2	Phase 1
	PF-04937319		Diabetes Mellitus-Type 2	Phase 1
	PF-04634817		Diabetic Nephropathy	Phase 1
	PF-04991532		Diabetes Mellitus-Type 2	Phase 1
	► PF-05175157		Diabetes Mellitus-Type 2	Phase 1
	► PF-05190457		Diabetes Mellitus-Type 2	Phase 1
	RN316 (PF-04950615)		Atherosclerosis (Biologic)	Phase 1

New Molecular Entity

New Indication or Enhancement

► Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com



Pfizer Pipeline – February 28, 2011 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Inflammation and Immunology	tofacitinib (formerly tasocitinib - CP-690550)	JAK Inhibitor	Rheumatoid Arthritis	Phase 3
	tofacitinib (formerly tasocitinib - CP-690550)	JAK Inhibitor	Psoriasis (Oral)	Phase 3
	PF-04171327		Rheumatoid Arthritis	Phase 2
	fezakinumab (ILV-094)		Rheumatoid Arthritis, *Psoriasis (Biologic)	Phase 2
	SBI-087 (PF-05230895)		Rheumatoid Arthritis, *Lupus (Biologic)	Phase 2
	ozoralizumab (ATN-103)		Rheumatoid Arthritis (Biologic)	Phase 2
	tofacitinib (formerly tasocitinib - CP-690550)		Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis (Topical), Crohn's Disease, Ulcerative Colitis	Phase 2
	SD-6010		Osteoarthritis	Phase 2
	PF-04308515		Anti-Inflammatory	Phase 1
	ILV-095 (PF-05212368)		Psoriasis (Biologic)	Phase 1
	ATR-107 (PF-05230900)		Crohn's Disease (Biologic)	Phase 1
	▶ PF-05230905 (ATN-192)		Rheumatoid Arthritis (Biologic)	Phase 1
	PF-04236921		Rheumatoid Arthritis, Crohn's Disease, Lupus (Biologic)	Phase 1

New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

* Note: Additional indications in Phase 1



Pfizer Pipeline – February 28, 2011 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Neuroscience & Pain	▶ Tafamidis meglumine	Transthyretin (TTR) Dissociation Inhibitor	Transthyretin amyloid polyneuropathy	Registration
	Celebrex	COX-2	Chronic Pain	Registration
	bapineuzumab	Beta Amyloid Inhibitor	Alzheimer's Disease (Biologic)	Phase 3
	latrepirdine (Dimebon)	MpTp Modulator	Alzheimer's Disease	Phase 3
	latrepirdine (Dimebon)	MpTp Modulator	Huntington's Disease	Phase 3
	Lyrica	Alpha-2 Delta Ligand	Epilepsy Monotherapy	Phase 3
	Lyrica	Alpha-2 Delta Ligand	Central Neuropathic Pain due to Spinal Chord Injury	Phase 3
	Lyrica	Alpha-2 Delta Ligand	Peripheral Neuropathic Pain (U.S.)	Phase 3
	tanezumab	Nerve Growth Factor Inhibitor	OA Signs and Symptoms (Biologic) (On Clinical Hold)	Phase 3
	▶ Lyrica	Alpha-2 Delta Ligand	QD (once a day dosing)	Phase 3
	▶ PF-02545920		Schizophrenia	Phase 2
	PF-04494700		Alzheimer's Disease	Phase 2
	CP-601,927		Depression	Phase 2
	SAM-531 (PF-05212365)		Alzheimer's Disease, *Schizophrenia	Phase 2
	PF-04360365 (ponezumab)		Alzheimer's Disease (Biologic)	Phase 2
	▶ PF-03049423		Stroke Recovery	Phase 2
	PH-797904		Pain	Phase 2

New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

* Note: Additional indications in Phase 1



Pfizer Pipeline – February 28, 2011 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Neuroscience & Pain (cont'd)	PF-04191834		Pain	Phase 2
	tanezumab		Cancer Pain (Biologic)	Phase 2
	▶ PF-05236812 (AAB-003)		Alzheimer's Disease (Biologic)	Phase 1
	PF-04958242		Schizophrenia	Phase 1
	Vabicaserin (PF-05208769)		Schizophrenia	Phase 1
	PF-05212377 (SAM-760)		Alzheimer's Disease	Phase 1
	PF-04427429		Migraine (Biologic)	Phase 1
	▶ PF-05089771		Chronic Pain	Phase 1
	PF-04531083		Severe Chronic Pain	Phase 1
	PF-04995274		Alzheimer's Disease	Phase 1

New Molecular Entity

New Indication or
Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com



Pfizer Pipeline – February 28, 2011 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Oncology	Sutent	Multiple Tyrosine Kinase Inhibitor	Islet Cell Tumors of the Pancrease	Registration (US); <i>approved in EU in December 2010</i>
	axitinib	VEGF Tyrosine Kinase Inhibitor	Renal Cell Carcinoma	Phase 3
	PF-00299804	pan-HER Inhibitor	Lung Cancer	Phase 3
	bosutinib	Abl and src-family kinase inhibitor	Chronic Myelogenous Leukemia	Phase 3
	neratinib	pan-HER Inhibitor	Breast Cancer	Phase 3
	PF-02341066 (crizotinib)	c-MET-ALK Inhibitor	Lung Cancer, *Cancer	Phase 3
	Sutent	Multiple Tyrosine Kinase Inhibitor	Renal Cell Carcinoma Adjuvant	Phase 3
	Torisel	FKBP-Rapamycin Associated Protein	Renal Cell Carcinoma	Phase 3
	▶ inotuzumab ozogamicin (CMC-544)		Aggressive Non-Hodgkin's Lymphoma (Biologic)	Phase 3
	inotuzumab ozogamicin (CMC-544)		Indolent Non-Hodgkin's Lymphoma (Biologic)	Phase 2
	axitinib		Lung Cancer, Thyroid Cancer	Phase 2
	CP-675206 (tremelimumab)		Genitourinary, Gastrointestinal Cancers, Melanoma, *Renal Cell Carcinoma, *Pancreatic (Biologic)	Phase 2
	PF-00299804		Cancer	Phase 2
	PD-0332991		Cancer	Phase 2
	PF-01367338		Cancer	Phase 2
	CVX 060 (PF-04856884)		Cancer (Biologic)	Phase 1
	CVX 241 (PF-05057459)		Cancer (Biologic)	Phase 1
	PF-03084014		Cancer	Phase 1

New Molecular Entity

New Indication or
Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

* Note: Additional indications in Phase 1



Pfizer Pipeline – February 28, 2011 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Oncology (cont'd)	PF-03446962		Cancer (Biologic)	Phase 1
	PF-05212384 (PKI-587)		Cancer	Phase 1
	PF-03758309		Cancer	Phase 1
	PF-04554878		Cancer	Phase 1
	PF-04605412		Cancer (Biologic)	Phase 1
	PF-04691502		Cancer	Phase 1
	PF-00562271		Cancer	Phase 1
	PF-04449913		Cancer	Phase 1
Vaccines	▶ Prevenar/Prevnar 13 Adult	Prophylactic Vaccine	Pneumococcal Disease	Registration
	ACC-001 (PF-05236806)		Alzheimer's Disease	Phase 2
	MnB rLP2086 (PF-05212366)		Adolescent Meningitis, *Infant Meningitis	Phase 2
	3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) (PF-05230894)		Staph Aureus	Phase 1

New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

* Note: Additional indications in Phase 1



Pfizer Pipeline – February 28, 2011 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Other Areas of Focus	Taliglucerase alfa	Enzyme Replacement Therapy	Gaucher Disease (Biologic)	Registration
	Macugen	Extracellular VEGF Antagonist	Diabetic Macular Edema (Biologic) (E.U.)	Registration
	► Xiapex (E.U.)	Clostridial Collagenase for Injection	Peyronie's Disease (Biologic) (E.U.)	Phase 3
	Eraxis/Vfend	Beta-D Glucan Synthase Inhibitor, Cyp P450 Mediated Alpha-lanosterol Demethylation	Aspergillosis	Phase 3
	Zithromax/chloroquine	5-OS Ribosome Inhibitor	Malaria	Phase 3
	Moxidectin	Glutamate-gated chloride channel binding	Onchocerciasis (River Blindness)	Phase 3
	bazedoxifene-conjugated estrogens (Aprela)	Tissue Selective Estrogen Complex	Menopausal Vasomotor Symptoms	Phase 3
	tofacitinib (formerly tasocitinib - CP-690550)		Transplant Rejection, Dry Eye	Phase 2
	► bosutinib		Autosomal Dominant Polycystic Kidney Disease	Phase 2
	PF-00868554 (filibuvir)		Hepatitis C Virus	Phase 2
	PF-04523655		Diabetic Macular Edema, Age-Related Macular Degeneration (Biologic)	Phase 2
	PF-04217329 (taprenepag isopropyl)		Glaucoma	Phase 2
	Terguride		Pulmonary Arterial Hypertension	Phase 2
	PH-797804		Chronic Obstructive Pulmonary Disease	Phase 2
	PF-03635659		Chronic Obstructive Pulmonary Disease	Phase 2
	PF-00610355		Chronic Obstructive Pulmonary Disease	Phase 2
	UK-396082		Pulmonary Fibrosis	Phase 1
	► PF-04136309		Liver Fibrosis	Phase 1

New Molecular Entity

New Indication or Enhancement

► Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com



Pfizer Pipeline – February 28, 2011 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Other Areas of Focus (cont'd)	▶ PF-04634817		Liver Fibrosis	Phase 1
	RN6G (PF-04382923)		Age-Related Macular Degeneration (Biologic)	Phase 1
	PNU-100480 (formerly PF-2341272)		Tuberculosis	Phase 1
	PF-03715455		Chronic Obstructive Pulmonary Disease	Phase 1
	▶ PF-05212372 (PLA-950)		Asthma	Phase 1
	PF-03526299		Asthma	Phase 1
	PF-03893787		Asthma	Phase 1
	PF-04764793 (PF-00241939)		Asthma	Phase 1
	PF-00489791		Chronic Renal Failure	Phase 1
	PF-04967544		Genitourinary	Phase 1
BMP-655 (PF-05208762)		Tendon Repair (Biologic)	Phase 1	

New Molecular Entity

New Indication or
Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com



Projects Discontinued from Development since September 27, 2010

Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Lyrica	Alpha-2 Delta Ligand	Generalized Anxiety Disorder (Monotherapy)	Registration
Lyrica	Alpha-2 Delta Ligand	Post Operative Pain	Phase 3
apixaban	Factor Xa Inhibitor	Acute Coronary Syndrome	Phase 3
Thelin	Endothelin A Receptor Antagonist	Pulmonary Hypertension	Phase 3
PF-04447943		Alzheimer's Disease	Phase 2
PF-03654746		Excessive Daytime Sleepiness, *Alzheimer's Disease	Phase 2
PF-4856881 Adolor		Chronic Pain	Phase 2 (Will be returned to Adolor in March 2011)
figitumumab		Gastrointestinal Cancers, Genitourinary, Ewing's Sarcoma, Small Cell Lung Cancer, Breast Cancer(Biologic)	Phase 2
Chantix		Cognition in Alzheimer's Disease	Phase 2
PF-03463275		Schizophrenia	Phase 2
PF-02400013		Schizophrenia	Phase 1
AGG-523 (PF-05212371)		OA Signs & Symptoms	Phase 1
PF-05161704		Diabetes Mellitus-Type 2	Phase 1
PF-03732010		Cancer (Biologic)	Phase 1
PF-04217903		Cancer	Phase 1

New Molecular Entity

New Indication or Enhancement

* Note: Additional indications in Phase 1

